Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SHR-A2102 and Adebrelimab

Phase 3Monoclonal antibody

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced or Metastatic Urothelial CarcinomaRecruiting

Locally Advanced or Metastatic Urothelial CarcinomaPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Locally Advanced or Metastatic Urothelial Carcinoma

NCT07393542

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Urothelial Carcinoma1 trial

An Open Label, Randomized, Multicenter, Phase III Study of SHR-A2102 in Combination With Adebrelimab Versus Gemcitabine in Combination With Cisplatin/Carboplatin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (NEC-UC2)

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07393542·453 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR-A2102 and Adebrelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR-A2102 and Adebrelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR-A2102 and Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Suncadia Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Related News